{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Xeris Biopharma Holdings, Inc.
Xeris Biopharma Faces Weak Start with 15% Gap Down Amid Market Concerns
Xeris Biopharma Holdings, Inc. opened with a notable loss, reflecting a significant decline in its stock performance over the past day and month. Despite this downturn, technical indicators show mixed signals, while the company maintains a market capitalization of approximately USD 1,255 million and a high return on equity.
Xeris Biopharma Hits New 52-Week High of $10.03, Up 314.66%
Xeris Biopharma Holdings, Inc. achieved a new 52-week high of USD 10.03 on October 29, 2025, reflecting a 314.66% increase over the past year. The company, despite being loss-making, has shown strong financial metrics and a market capitalization of USD 1,255 million in the biotechnology sector.
Xeris Biopharma Hits New 52-Week High of $9.48, Up 297% Year-Over-Year
Xeris Biopharma Holdings, Inc. achieved a new 52-week high of USD 9.48 on October 24, 2025, reflecting a 296.98% increase over the past year. The company, with a market cap of USD 1,255 million, shows strong financial metrics despite being currently loss-making and lacking a dividend yield.
Xeris Biopharma Hits Day High with 14.16% Surge in Stock Price
Xeris Biopharma Holdings, Inc. has seen a notable rise in its stock price, reflecting strong performance in the pharmaceuticals sector. Over the past year, the company has achieved impressive returns, significantly outpacing the S&P 500. Despite challenges like a negative book value, recent quarterly results show positive growth.
Xeris Biopharma Hits New 52-Week High of $9.29, Up 299.57%
Xeris Biopharma Holdings, Inc. achieved a new 52-week high of USD 9.29 on October 15, 2025, marking a significant performance increase of 299.57% over the past year. The company, despite being unprofitable, boasts a market capitalization of USD 1,255 million and strong financial metrics in the biotechnology sector.
Xeris Biopharma Reaches New 52-Week High of $8.51, Up 253%
Xeris Biopharma Holdings, Inc. achieved a new 52-week high of USD 8.51, reflecting a significant year-over-year performance increase. With a market capitalization of approximately USD 1,255 million, the company has notable financial metrics, including a high return on equity, despite currently being loss-making and not offering dividends.
Xeris Biopharma Hits New 52-Week High of $8.35, Up 232.76%
Xeris Biopharma Holdings, Inc. achieved a new 52-week high of USD 8.35 on September 19, 2025, reflecting a significant growth trajectory over the past year. The company, with a market capitalization of USD 1,255 million, operates in the Pharmaceuticals & Biotechnology sector and has a notable return on equity.
Is Xeris Biopharma Holdings, Inc. technically bullish or bearish?
As of August 1, 2025, Xeris Biopharma Holdings, Inc. shows a bullish technical trend, supported by positive MACD and moving averages, despite a bearish weekly RSI and mixed signals, while significantly outperforming the S&P 500 with a year-to-date return of 144.84%.
Xeris Biopharma Hits Day High with Strong 8.21% Intraday Surge
Xeris Biopharma Holdings, Inc. has shown remarkable stock performance, gaining 8.21% on September 18, 2025, and achieving a 257.76% increase over the past year. The company reported significant growth in operating profit and net sales, with strong institutional interest reflected in 65.86% holdings.
Xeris Biopharma Hits New 52-Week High of $8.34, Up 257.76%
Xeris Biopharma Holdings, Inc. achieved a new 52-week high of USD 8.34, reflecting significant growth from its previous low of USD 2.69. The company has seen a remarkable one-year performance increase of 257.76%, with a market capitalization of USD 1,255 million and a notable return on equity of 167.94%.
Is Xeris Biopharma Holdings, Inc. overvalued or undervalued?
As of August 13, 2018, Xeris Biopharma Holdings, Inc. is considered risky and overvalued due to negative financial metrics, including a Price to Book Value of -20.88 and a P/E ratio of -15.77, despite a strong stock performance of 119.91% over the past year.
Is Xeris Biopharma Holdings, Inc. technically bullish or bearish?
As of May 21, 2025, Xeris Biopharma Holdings, Inc. shows a mildly bullish trend due to positive daily moving averages and monthly MACD signals, though caution is advised from mixed weekly indicators and a lack of strong conviction in price movement.
Who are in the management team of Xeris Biopharma Holdings, Inc.?
As of March 2022, the management team of Xeris Biopharma Holdings, Inc. includes Paul Edick as Chairman and CEO, with John Schmid as Lead Independent Director and independent directors BJ Bormann, Dawn Halkuff, Marla Persky, and Jeffrey Sherman.
What does Xeris Biopharma Holdings, Inc. do?
Xeris Biopharma Holdings, Inc. is a specialty pharmaceutical company focused on developing injectable and infusible drug formulations. As of March 2025, it reported net sales of $60 million and a net loss of $9 million, with a market cap of $727.10 million.
How big is Xeris Biopharma Holdings, Inc.?
As of Jun 18, Xeris Biopharma Holdings, Inc. has a market capitalization of $727.10 million, with net sales of $222.55 million and a net profit of -$45.08 million over the last four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
